Korshunov A G, Shishkina L V, Golanov A V
N.N. Burdenko Research Institute of Neurosurgery, 125047, Moscow.
Arkh Patol. 2002 Jan-Feb;64(1):29-33.
Routine pathological examination cannot precisely predict the clinical course of meningiomas because even histologically benign tumors may recur after total removal. And so, numerous efforts have been made for evaluation of meningioma growth fraction and its prognostic value. In this study the prognostic significance of DNA toposiomerase II alpha (topoII) and cyclin A immunohistochemistry was examined in a series of 263 meningiomas. The topoII and cyclin A scores exhibited a close correlation with Ki-67 immunostaining. Significant differences between the indices for all the three markers were noted among the three grades of meningiomas. The scores for all the three markers were significantly different between recurrent and non-recurrent meningiomas including removed benign tumors. The most important information for an individual clinical outcome of histologically benign meningiomas should be elicited from simultaneous evaluation of all the three proliferative markers.
常规病理检查无法精确预测脑膜瘤的临床病程，因为即使是组织学上的良性肿瘤在全切后也可能复发。因此，人们为评估脑膜瘤的生长分数及其预后价值付出了诸多努力。在本研究中，对263例脑膜瘤进行了DNA拓扑异构酶IIα（topoII）和细胞周期蛋白A免疫组化的预后意义检测。topoII和细胞周期蛋白A评分与Ki-67免疫染色密切相关。在脑膜瘤的三个级别中，所有这三种标志物的指数存在显著差异。包括切除的良性肿瘤在内，复发和未复发的脑膜瘤之间，所有这三种标志物的评分均有显著差异。对于组织学上良性脑膜瘤的个体临床结局，最重要的信息应通过同时评估所有这三种增殖标志物来获取。
